TableĀ 4.
All patients |
ANA pos (N=288) |
ANA neg (N=259) |
Rate ratio* | p Value | ||||
---|---|---|---|---|---|---|---|---|
n | Per cent | n | Per cent | n | Per cent | |||
CLIFT 1 | 33 | 6.1 | 18 | 6.3 | 15 | 5.8 | 1.1 | 0.82 |
CLIFT 2 | 36 | 6.6 | 22 | 7.6 | 14 | 5.4 | 1.4 | 0.29 |
CLIFT 3 | 45 | 8.2 | 30 | 10.4 | 15 | 5.8 | 1.8 | 0.05 |
Any CLIFT | 59 | 10.8 | 39 | 13.5 | 20 | 7.7 | 1.75 | 0.03 |
EliA | 61 | 11.1 | 27 | 9.4 | 34 | 13.1 | 0.7 | 0.16 |
SPADE | 57 | 10.4 | 28 | 9.7 | 29 | 11.2 | 0.9 | 0.57 |
Varelisa 1 | 50 | 9.1 | 26 | 9.0 | 24 | 9.3 | 1 | 0.92 |
Varelisa 2 | 59 | 10.8 | 30 | 10.4 | 29 | 11.2 | 0.9 | 0.77 |
Any ELISA | 99 | 18.1 | 50 | 17.4 | 49 | 18.9 | 0.9 | 0.64 |
Any test | 124 | 22.7 | 68 | 23.6 | 56 | 21.6 | 1.1 | 0.58 |
CLIFT+ELISA | 34 | 6.2 | 21 | 7.3 | 13 | 5.0 | 1.6 | 0.27 |
Test details are presented in table 1.
*Ratio between prevalence of positive anti-dsDNA test in ANA positive and ANA-negative patients.
ANA, antinuclear antibodies; CLIFT, Crithidia Lucillia Immunofluorescence Test; SPADE, solution phase anti-dsDNA ELISA.